Biomarkers for neurodegenerative diseases aren't static; they fluctuate with circadian rhythms and environmental factors. This variability complicates drug activity assessment, as a single data point can be misleading. This suggests a need for more sophisticated, longitudinal tracking in clinical trials.
Focusing on breaking up protein aggregates may be intervening too late in neurodegenerative diseases. A more effective strategy could be targeting neuroinflammation, an upstream mechanism that potentially drives damage before irreversible protein aggregation begins and becomes a self-feeding cycle.
The staggering gender disparity in dementia (nearly 70% female patients) is rooted in historical exclusion from research. The fact that women's participation in US trials wasn't legally mandated until the 1990s highlights a massive, ignored opportunity to understand sex-based biology and develop more targeted therapeutics.
Despite high scientific risk, generalist investors are entering neuroscience because it's a massive, underserved market. The potential for significant returns from even incremental improvements, combined with the huge societal and economic impact, creates a strong financial thesis for this 'white space'.
A winding career path spanning academia, law, business, and operations is not a liability for a VC but a key advantage. This 'non-linear' experience builds a diverse toolkit of skills that is directly deployable to support portfolio companies at the board level, offering broader and more practical guidance.
To secure investment in the high-risk neurodegeneration space, companies must avoid significant 'leaps of faith.' A key de-risking factor is applying novel modalities to clinically validated pathways. This provides a stronger scientific foundation than pursuing a completely unproven biological hypothesis, making the venture more compelling to investors.